Advances of Marine-Derived Enzymes

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 996

Special Issue Editor


E-Mail Website
Guest Editor
Matís Ohf., Reykjavik, Iceland
Interests: biotechnology; genome/metagenome analysis; marine enzymes; marine polysaccharides; bioactive compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,                

Marine enzymes are different from terrestrial enzymes in many ways. They have evolved specificity and affinity for marine molecules, which are often recalcitrant to terrestrial enzymes. The diverse and complex marine environments with high salinity, high pressure, low temperature, and special lighting conditions have also contributed to their specific features. In recent years, interest in marine biotechnology has increased. Marine biomass, such as seaweed, can be considered a preferable alternative to terrestrial plants for refining nutrients, bioenergy compounds, bioactive molecules, and other chemicals, as the latter feedstock is reliant on water, land, fertilizers, and pesticides, and also competes with crops that are intended for human consumption. The enzymatic refining of marine feedstock such as seaweed to added value products is, however, still rare to find on an industrial scale. There is a need for suitable and advantageous enzymatic tools. The bioprospecting of marine enzymes with industrial application potentials is therefore still of great interest.

A Special Issue on advances in marine derived enzymes is now planned for publication in the journal Marine Drugs. The focus will be on enzymes from both marine microbial and multicellular organisms. New marine enzymes, enzyme products, properties, and production technology, as well as exploitation potential in marine biotechnology will be highlighted.

Dr. Olafur Fridjonsson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine enzymes
  • enzyme products
  • enzyme properties
  • exploitation potentials
  • marine biotechnology
  • biorefining
  • production technology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2442 KiB  
Article
Purification and Characterization of a Novel Fibrinolytic Enzyme from Marine Bacterium Bacillus sp. S-3685 Isolated from the South China Sea
by Zibin Ma, Jeevithan Elango, Jianhua Hao and Wenhui Wu
Mar. Drugs 2024, 22(6), 267; https://doi.org/10.3390/md22060267 - 10 Jun 2024
Viewed by 787
Abstract
A novel fibrinolytic enzyme, BSFE1, was isolated from the marine bacterium Bacillus sp. S-3685 (GenBank No.: KJ023685) found in the South China Sea. This enzyme, with a molecular weight of approximately 42 kDa and a specific activity of 736.4 U/mg, exhibited its highest [...] Read more.
A novel fibrinolytic enzyme, BSFE1, was isolated from the marine bacterium Bacillus sp. S-3685 (GenBank No.: KJ023685) found in the South China Sea. This enzyme, with a molecular weight of approximately 42 kDa and a specific activity of 736.4 U/mg, exhibited its highest activity at 37 °C in a phosphate buffer at pH 8.0. The fibrinolytic enzyme remained stable over a pH range of 7.5 to 10.0 and retained about 76% of its activity after being incubated at 37 °C for 2 h. The Km and Vmax values of the enzyme at 37 °C were determined to be 2.1 μM and 49.0 μmol min−1 mg−1, respectively. The fibrinolytic activity of BSFE1 was enhanced by Na+, Ba2+, K+, Co2+, Mn2+, Al3+, and Cu2+, while it was inhibited by Fe3+, Ca2+, Mg2+, Zn2+, and Fe2+. These findings indicate that the fibrinolytic enzyme isolated in this study exhibits a strong affinity for fibrin. Moreover, the enzyme we have purified demonstrates thrombolytic enzymatic activity. These characteristics make BSFE1 a promising candidate for thrombolytic therapy. In conclusion, the results obtained from this study suggest that our work holds potential in the development of agents for thrombolytic treatment. Full article
(This article belongs to the Special Issue Advances of Marine-Derived Enzymes)
Show Figures

Figure 1

Back to TopTop